Abstract P022

TREATMENT OF CLASSICAL HODGKIN'S LYMPHOMA (cHL) WITH BRENDUXIMAB VEDOTIN - DOXORUBICIN – VINBLASTINE – DACARBAZINE (BV-AVD). ONE CENTER’S EXPERIENCE

BACKROUND: According to the ECHELON-1 study, administration of the combination has been widely adopted in the treatment of advanced stage HL. Additionally, other clinical trials tested the administration of this treatment in limited stage disease. Despite its effectiveness, toxicity is questionable, limiting its administration to younger patients. In our work we deposit the experience of our Center in the administration of BV-AVD.

MATERIAL & METHODS: We retrospectively collected the data of 20 consecutive patients with cHL treated in our Centre with the BV-AVD combination during the last 7 years. All but one were younger than 40 years old. We studied effectiveness as well as toxicity profile of the combination.

RESULTS: Ten men and 10 women, with a median age of 32.4 years (range 17.3 – 71.6) were diagnosed with cHL between 2017 and 2023. Histological subtype was nodular sclerosis (NS) in 14 patients, mixed cellularity (MC) in 4 patients, while in 2 it was not possible to determine disease subtype due to limitations of biopsy sample. The Ann Arbor stage of the disease was I (n=1), II (n=8), III (n=6), IV (n=5). Eight (40%) patients presented with B-symptoms at diagnosis. Two patients were diagnosed with bulky disease. Three patients had limited stage disease, while 17 had advanced disease: early unfavorable n=6, stage III - IV n=11. Eighteen patients had performance status ECOG 0-1. All completed 6 cycles, except of 2 patients, who received 4. None received adjuvant radiotherapy. Eighteen out of 20 patients achieved metabolic remission after the 2nd cycle. Two patients had interim PET/CT assessed as Deauville Scale 4. All achieved complete metabolic response at the end of the treatment program. Progression under treatment or disease relapse was not occurred to anyone. All received prophylactic granulocyte-colony growth factor. Four patients manifested febrile neutropenia and 4 lower respiratory tract infection. Six (32%) presented with any grade peripheral neuropathy, while 2 developed grade 3. Particularly frequent (42%) were intestinal side effects: diarrhea, constipation, ileus, and 1 patient presented with pancreatitis. With a median follow-up of 48 months (range 3.2 – 69.6), all patients are alive and in complete remission but one, who died of a non-disease-related cause.

CONCLUSION: BV-AVD combination is effective, although accompanying toxicity limits its administration to younger patients.

Authors

Chara Giatra, Andri Polyviou, Kyriaki Kontitsi, Tatiana Tzenou, Michael Panousieris, Vasiliki Babali, Athanasia Apsemidou, Sotiris Bristogiannis, Athanasios Gakopoulos, Evridiki Theodorou, George Kanellis, Ioannis Baltadakis, Stavros Gigantes, Maria Bouzani